g plan semaglutide G-Plans: Combining Telehealth and GLP-1s A Multidisciplinary Perspective on Semaglutide

Hims made ~$225 million in GLP-1 revenue in 2024, while acknowledging that many of those members from 2024 will explore other branded options when it stops offering commercially available doses of semaglutide after Q1 2025

2014;103(3):e379

Available from: Rucker D, Padwal R, Li SK, et al

Choosing between Tesamorelin and CJC-1295 depends on your individual goals and needs: For Fat Loss : If your primary goal is to reduce visceral fat, especially in the abdominal region, Tesamorelin may be the better option

Plus, its lightweight texture layers easily with other products

doi: 10.3389/fbioe.2023.1279270 Received 17 August 2023 Accepted 17 October 2023 Published 30 October 2023 Volume 11 - 2023 Edited by Balaram Mohapatra, Gujarat Biotechnology Research Centre (GBRC), India Reviewed by Y